Share This Page:   

 

Browse by Clinical Topic:
Select a Topic to Learn More

Featured CME/CE Content:

 

neuroscienceCME Editors' Picks:

Sorting Out the Androgen Deprivation Therapy Options for Locally Advanced CSPC

Premiere Date: Tuesday, August 31, 2021

This activity offers CE credit for:

1. ABIM (MOC)
2. Medicine (accme)
3. Nursing (ANCC)
4. Pharmacy (acpe)
5. PA (aapa)
6. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date:
Wednesday, August 31, 2022
Note: Credit Is No Longer Available

Faculty

Cora N. Sternberg, MD, FACP (Moderator) Clinical Director, Englander Institute for Precision Medicine Professor of Medicine Sandra and Edward Meyer Cancer Center Weill Cornell Medicine New York, NY

Neal D. Shore, MD, FACS  Director, CPI, Carolina Urologic Research Center Chief Surgical Officer, Genesis Care, US Atlantic Urology Clinics Myrtle Beach, SC

Statement of Need

Despite the development of investigational and therapeutic options for prostate cancer, a lack of consensus among clinicians regarding patient management in early disease stages remains. Patients with locally advanced or metastatic castration-sensitive prostate cancer should receive androgen deprivation therapy (ADT) after definitive therapy, and it is imperative that clinicians consider luteinizing hormone releasing hormone (LHRH) antagonists in patients with major adverse cardiovascular events (MACE) risk factors. Additionally, must weigh factors that might negatively impact ADT adherence against the choice of ADT. This CMEOCast episode will aim to improve knowledge and competence in integrating the latest data on the management of patients with early-stage prostate cancer by evaluating strategies for its management and differentiating the potential for adverse effects between androgen deprivation therapies

Learning Objectives

At the end of this CE activity, participants should be able to:

• Evaluate strategies for the management of locally advanced castrate-sensitive prostate cancer.
• Differentiate the potential for adverse effects between androgen-deprivation therapies.

Financial Support

Supported by an educational grant from Astellas and Pfizer, Inc.

Target Audience

Urologists, medical oncologists, PAs, nurse practitioners, and pharmacists

Credit Information

ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to .75 medical knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC:Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Sternberg reports that is a consultant for Astellas Pharma US, Inc.; AstraZeneca; Bristol-Myers Squibb Company; Foundation Medicine, Inc.; Immunomedics, Inc./Gilead Sciences, Inc.; Incyte; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Merck Sharp & Dohme Corp.; National Cancer Institute; Pfizer Inc.; Genentech, Inc./Roche; Sanofi Genzyme; and UroToday.

Dr. Shore reports he serves on the speakers bureau for AstraZeneca; Astellas Pharma US, Inc.; Bayer; Clovis Oncology; Foundation Medicine, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. He is a consultant for Speakers Bureau: AstraZeneca; Astellas Pharma US, Inc.; Bayer; Clovis Oncology; Foundation Medicine, Inc.; Guardant Health; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; and Pfizer Inc. Consultant: AbbVie Inc.; Amgen Inc.; Astellas Pharma US, Inc.; AstraZeneca; Bayer; Boston Scientific Corporation; Bristol-Myers Squibb Company; Clovis Oncology; Cold Genesys; Dendreon Pharmaceutical LLC; Exact Imaging; Exact Sciences Corporation; FerGene Inc.; Foundation Medicine, Inc.; GenesisCare; Invitae Corporation; Janssen Pharmaceuticals, Inc.; MDxHealth; Merck & Co., Inc.; Myovant Sciences; Myriad Genetics, Inc.; Nymox Pharmaceuticals Corporation; Pacific Edge; Pfizer Inc.; Phosphorous; PreVie; Propella Therapeutics, Inc.; Sanofi Genzyme; Sesen Bio; Speciality Networks, LLC; Tolmar Pharmaceuticals, Inc.; and UroGen Pharma, Inc.

David Modrak, PhD (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

CME Outfitters, LLC and the faculty do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).